Danny Rischin
#162,156
Most Influential Person Now
Australian oncologist
Danny Rischin's AcademicInfluence.com Rankings
Danny Rischinphilosophy Degrees
Philosophy
#9388
World Rank
#12941
Historical Rank
Logic
#6367
World Rank
#7879
Historical Rank

Download Badge
Philosophy
Danny Rischin's Degrees
- Bachelors Medicine University of Melbourne
- PhD Cancer Biology University of Melbourne
Why Is Danny Rischin Influential?
(Suggest an Edit or Addition)Danny Rischin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (2003) (2937)
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (2019) (1244)
- Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. (2002) (835)
- PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma (2018) (807)
- Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. (2010) (692)
- Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. (2010) (656)
- Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. (2006) (534)
- Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. (2002) (516)
- Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. (2003) (433)
- Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. (2010) (349)
- Head and Neck Squamous Cell Carcinoma (2020) (336)
- Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. (2005) (304)
- Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. (2009) (298)
- Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. (1996) (256)
- Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer (2005) (253)
- Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). (2005) (251)
- Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. (2018) (235)
- IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer (2011) (225)
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. (2010) (225)
- High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07. (2003) (214)
- An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. (2005) (213)
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. (2020) (212)
- F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma (2001) (210)
- Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. (2012) (203)
- Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. (2001) (202)
- The 'QUAD SHOT'--a phase II study of palliative radiotherapy for incurable head and neck cancer. (2005) (195)
- Phase II study of imatinib in patients with small cell lung cancer. (2003) (183)
- Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. (2004) (169)
- Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? (2006) (166)
- Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. (2005) (156)
- Clinical impact of, and prognostic stratification by, F‐18 FDG PET/CT in head and neck mucosal squamous cell carcinoma (2007) (150)
- Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation (2009) (150)
- Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent (2005) (142)
- Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. (2002) (136)
- KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2018) (128)
- Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study (2010) (123)
- N2‐N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders—Results of Trans Tasman Radiation Oncology Group Study 98.02 (2008) (118)
- Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma (2004) (116)
- Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation (2008) (114)
- Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. (2018) (114)
- Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2019) (111)
- Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. (2018) (104)
- Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. (1998) (99)
- Impact of Positron Emission Tomography on the Management of Patients With Small-Cell Lung Cancer: Preliminary Experience (2004) (99)
- Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition (2016) (99)
- Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. (2003) (98)
- A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors (2010) (92)
- The usefulness of fluorine 18–labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor (2003) (90)
- Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus (2020) (88)
- Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer (2013) (85)
- Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma (2011) (84)
- Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma (2018) (83)
- Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. (1997) (81)
- Survival with Cemiplimab in Recurrent Cervical Cancer. (2022) (80)
- Paranasal sinus tumors: Peter maccallum cancer institute experience (2004) (80)
- Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing (2020) (79)
- Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) (2016) (77)
- Usefulness of fluorine‐18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck (2004) (75)
- Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. (1996) (74)
- How do oncologists deal with incidental abnormalities on whole‐body fluorine‐18 fluorodeoxyglucose PET/CT? (2007) (70)
- Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study (2007) (69)
- Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. (1999) (69)
- What is the best treatment for patients with human papillomavirus–positive and –negative oropharyngeal cancer? (2014) (68)
- Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) (2000) (68)
- A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. (2002) (65)
- Imaging of hypoxia with 18F‐FAZA PET in patients with locally advanced non‐small cell lung cancer treated with definitive chemoradiotherapy (2013) (63)
- Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. (2002) (61)
- Frequency and prognostic significance of p16INK4A protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma (2015) (60)
- Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. (2015) (59)
- Optimising the therapeutic ratio in head and neck cancer. (2010) (58)
- Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma. (2011) (58)
- Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome (2014) (58)
- Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer. (2000) (57)
- Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. (1996) (57)
- Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. (2011) (57)
- Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. (2003) (56)
- Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer (2012) (55)
- Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute. (1996) (55)
- Merkel cell carcinoma: emerging biology, current approaches, and future directions. (2015) (55)
- High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. (2009) (51)
- Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. (2008) (50)
- Oropharyngeal cancer, human papilloma virus, and clinical trials. (2010) (49)
- De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies (2020) (48)
- Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. (2018) (47)
- Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274). (2021) (47)
- Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial (2011) (47)
- Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation (2011) (45)
- Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. (2002) (45)
- Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. (2011) (45)
- Analysis of toxicity of Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group study. (2001) (43)
- Weekly carboplatin reduces toxicity during synchronous chemoradiotherapy for Merkel cell carcinoma of skin. (2008) (43)
- Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. (2009) (42)
- FDG-PET-Detected Extracranial Metastasis in Patients with Non-Small Cell Lung Cancer Undergoing Staging for Surgery or Radical Radiotherapy (2003) (41)
- A randomised crossover trial of chemotherapy in the home: patient preferences and cost anaiysis (2000) (41)
- Radiation recall reaction following gemcitabine. (2001) (41)
- Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. (2007) (40)
- Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). (2017) (39)
- Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose. (2013) (38)
- Prospective trial to evaluate staged neck dissection or elective neck radiotherapy in patients with CT‐staged T1‐2 N0 squamous cell carcinoma of the oral tongue (2009) (38)
- Randomised trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01) - a Trans-Tasman Radiation Oncology Group study. (2021) (38)
- Phase I trial of cremophor EL with bolus doxorubicin. (1998) (37)
- Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma. (2004) (37)
- Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. (2001) (37)
- PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. (2020) (36)
- Tonsillar cancer: The Peter MacCallum experience with unilateral and bilateral irradiation (2014) (36)
- BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma. (2016) (36)
- Overview of Advances in Head and Neck Cancer. (2015) (36)
- Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study (2020) (36)
- A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. (2002) (36)
- Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial (2005) (36)
- Suboptimal health literacy in patients with lung cancer or head and neck cancer (2013) (36)
- Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide (1997) (34)
- Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line (1999) (34)
- Prospective analysis of the utility of 18‐FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03 (2018) (33)
- Timely initiation of chemotherapy: a systematic literature review of six priority cancers – results and recommendations for clinical practice (2017) (33)
- The role of human papillomavirus in p16‐positive oral cancers (2018) (33)
- p16‐positive lymph node metastases from cutaneous head and neck squamous cell carcinoma: No association with high‐risk human papillomavirus or prognosis and implications for the workup of the unknown primary (2016) (32)
- Correlation of p16 status, hypoxic imaging using [18F]‐misonidazole positron emission tomography and outcome in patients with loco‐regionally advanced head and neck cancer (2014) (32)
- Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. (2013) (31)
- Relapse patterns in WHO 2/3 nasopharyngeal cancer: is there a difference between ethnic Asian vs. non-Asian patients? (2006) (31)
- Phase 1 Study of Tirapazamine in Combination With Radiation and Weekly Cisplatin in Patients With Locally Advanced Cervical Cancer (2010) (30)
- Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. (2022) (30)
- A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis (2001) (30)
- Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients (2004) (29)
- Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. (1998) (29)
- A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. (2013) (29)
- Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up. (2020) (28)
- Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis (2021) (28)
- Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial (2010) (28)
- Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer. (2004) (28)
- The utility of PET/CT in staging and assessment of treatment response of nasopharyngeal cancer (2011) (27)
- Strategies to overcome accelerated repopulation and hypoxia--what have we learned from clinical trials? (2004) (27)
- A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. (2000) (27)
- Individualised mindfulness‐based stress reduction for head and neck cancer patients undergoing radiotherapy of curative intent: a descriptive pilot study (2017) (27)
- Frequency and prognostic significance of p16 INK4A protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma (2015) (27)
- Recent Insights and Advances in the Management of Merkel Cell Carcinoma. (2016) (27)
- Association of acquired Pelger‐Huet anomaly with taxoid therapy (1996) (27)
- Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (2008) (27)
- Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01. (2007) (26)
- A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck (2007) (26)
- The impact of preradiation residual disease volume on time to locoregional failure in cutaneous Merkel cell carcinoma--a TROG substudy. (2013) (26)
- A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174). (2014) (26)
- Non-smoking, non-drinking elderly females, a 5 year follow-up of a clinically distinct cohort of oral squamous cell carcinoma patients. (2018) (26)
- Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. (2019) (25)
- Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC). (2019) (25)
- Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. (2020) (25)
- Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score (2022) (25)
- The Utility of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography in the Investigation of Patients with Disseminated Carcinoma of Unknown Primary Origin (2005) (24)
- Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. (2011) (23)
- Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer (2010) (23)
- Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer (2014) (23)
- Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer. (2012) (23)
- 18F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data (2015) (22)
- PRISM: Phase 2 trial with panitumumab monotherapy as second‐line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (2016) (22)
- Quantitative and qualitative analysis of [18F]FDG and [18F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome (2016) (21)
- Impact of center size and experience on outcomes in head and neck cancer. (2015) (21)
- Developing a performance data suite to facilitate lean improvement in a chemotherapy day unit. (2013) (21)
- Sinonasal malignancies of neuroendocrine origin. (2008) (20)
- Diabetes associated with immune checkpoint inhibition: presentation and management challenges (2018) (20)
- A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. (2004) (20)
- Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors (2020) (20)
- Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature (2001) (20)
- Treatment response in the neck: p16+ versus p16− oropharyngeal cancer (2013) (19)
- T4 squamous cell carcinoma of the oral tongue without mandibular involvement: surgery or chemoradiotherapy? (2014) (19)
- PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. (2005) (19)
- Safety and cost analysis of an (18)FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation. (2015) (19)
- Oral cyclophosphamide in recurrent ovarian cancer (2016) (19)
- Phase 1 study of a focal adhesion kinase (FAK) inhibitor PF-00562271 in patients (pts) with advanced solid tumors (2007) (19)
- Abiraterone in metastatic salivary duct carcinoma. (2015) (19)
- Promising Results of a Cooperative Group Phase II Trial of Preoperative Chemoradiation for Locally Advanced Rectal Cancer (TROG 9801) (2005) (19)
- Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome (2014) (18)
- The role of PET-CT in the management of patients with advanced cancer of the head and neck (2008) (18)
- Rectal Adenocarcinoma With Germ Cell Elements Treated With Chemotherapy (1993) (18)
- Subxiphoid partial pericardiectomy with or without sclerosant instillation in the treatment of symptomatic pericardial effusions in patients with malignancy (1991) (17)
- Larynx preservation for patients with locally advanced laryngeal cancer. (2013) (17)
- Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC) (2019) (17)
- A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC (2005) (16)
- Elusive goal of targeting tumor hypoxia for therapeutic gain. (2012) (16)
- Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. (2003) (16)
- Docetaxel effectively mobilizes peripheral blood CD34+ cells (2000) (16)
- Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. (1999) (16)
- Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: a case report and review of the literature. (2001) (16)
- Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck. (2000) (16)
- Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the delivery of postoperative radiation therapy in complex cutaneous squamous cell carcinoma of the head and neck (cSCCHN). (2020) (16)
- Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses (2020) (15)
- ZD0473 phase II monotherapy trial in second-line ovarian cancer (2001) (15)
- KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). (2020) (15)
- Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. (2002) (15)
- 986ORANDOMIZED PHASE II STUDY OF MEHD7945A (MEHD) VS CETUXIMAB (CET) IN >= 2ND-LINE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD & NECK (RMSCCHN) PROGRESSIVE ON/AFTER PLATINUM-BASED CHEMOTHERAPY (PTCT). (2014) (15)
- A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669. (2018) (14)
- Parotid-sparing radiotherapy: does it really reduce xerostomia? (2005) (14)
- Identification of an excellent prognosis subset of human papillomavirus associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. (2019) (14)
- Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls (2011) (13)
- CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy. (2002) (13)
- Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy. (2002) (13)
- Larynx preservation with primary non‐surgical treatment for loco‐regionally advanced larynx cancer (2011) (13)
- A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies (2018) (13)
- Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis (2020) (13)
- Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV+ oropharyngeal squamous cell carcinoma. (2019) (13)
- KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). (2017) (13)
- Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study (2022) (13)
- 8 Extraordinary tumor control in phase I trial of concurrent tirapazamine cisplatin and radiotherapy for far advanced head and neck cancer (1999) (12)
- Radiation with cisplatin or carboplatin for locally advanced cervix cancer: The experience of a tertiary cancer centre (2013) (12)
- Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. (2019) (11)
- Prolonged remission in a patient with nasopharyngeal carcinoma with a solitary bone metastasis. (2011) (11)
- INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors. (2017) (11)
- Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer (1999) (11)
- Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval. (2002) (11)
- Fear of Cancer Recurrence in Survivors of Human Papillomavirus-Associated Oropharyngeal Carcinoma. (2021) (11)
- A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL. (2012) (10)
- Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study (2000) (10)
- Multidrug resistance in leukemia. (1993) (10)
- Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC) (2019) (10)
- Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus–positive oropharyngeal squamous cell carcinoma (2016) (10)
- Ovarian Growing Teratoma Syndrome With Spuriously Elevated α-Fetoprotein. (2015) (10)
- Phase II Trial of Continuous Infusion Carboplatin, 5-Fluorouracil, and Radiotherapy for Localized Cancer of the Esophagus (2002) (10)
- Unilateral radiotherapy treatment for p16/human papillomavirus–positive squamous cell carcinoma of unknown primary in the head and neck (2018) (10)
- Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services (2016) (10)
- Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and GM-CSF in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. (2021) (9)
- Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC). (2020) (9)
- A phase II trial of paclitaxel and epirubicin in advanced breast cancer (2000) (9)
- Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial. (2020) (9)
- A randomised trial of dexamethasone, lorazepam and prochlorperazine for emesis in patients receiving chemotherapy. (1992) (9)
- Review : Cremophor: Pharmacological activity of an "inert" solubiliser (1997) (9)
- Post-operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: A randomized phase III trial (Trans Tasman Radiation Oncology Group 05.01 Trial; POST study). (2017) (9)
- Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma. (2012) (9)
- Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation (2017) (8)
- Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). (2020) (8)
- Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. (2001) (8)
- Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas (2015) (8)
- LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) (2022) (8)
- INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors. (2020) (7)
- The local-regionally advanced nasopharyngeal carcinoma jigsaw puzzle: where does the chemotherapy piece fit? (2002) (7)
- Intraperitoneal distribution imaging in ovarian cancer patients (2011) (7)
- Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis (2015) (7)
- Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre (2020) (7)
- Efficacy of erlotinib in patients with advanced Non‐small‐cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study (2012) (7)
- Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer. (1997) (7)
- Clinical verification of the superiority of the current International Union Against Cancer staging criteria in an Australian population of patients with nasopharyngeal carcinoma. (2004) (7)
- Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC). (2018) (7)
- Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma (2020) (7)
- 'Boomerang' technique: an improved method for conformal treatment of locally advanced nasopharyngeal cancer. (2004) (7)
- Calculating carboplatin doses using the 4-variable modification of diet in renal disease (4-v MDRD) estimate of glomerular filtration rate (GFR) in the Calvert formula (2007) (7)
- Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin. (2017) (7)
- Phase I trial of cremophor EL and doxorubicin in advanced cancer: 100 (1994) (7)
- Intensity-modulated radiotherapy: examples of its utility in head and neck cancer. (2004) (7)
- Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre (2018) (7)
- Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors (2017) (6)
- Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer (2022) (6)
- Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG. (2017) (6)
- A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC). (2020) (6)
- Quantitative and qualitative analysis of [ 18 F]FDG and [ 18 F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome (2018) (6)
- Impact of histological Oral Tongue Cancer margins on locoregional recurrence: A multi-centre retrospective analysis. (2020) (6)
- Randomized trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01): A Trans-Tasman Radiation Oncology Group study. (2021) (6)
- A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy (2004) (6)
- Induction chemotherapy in head and neck cancer: closer to an answer? (2011) (6)
- Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study. (2018) (6)
- FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma (2021) (6)
- Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care. (2020) (6)
- Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (2018) (5)
- Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer - A review of the literature and PRO methodology. (2021) (5)
- High-Dose Cisplatin for Head and Neck Cancer Lives On. (2018) (5)
- First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1. (2018) (5)
- First-in-man trial of 4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid (PENAO) as a continuous intravenous infusion (CIVI), in patients (pt) with advanced solid tumours. (2016) (5)
- GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer. (2018) (5)
- Merkel cell carcinoma – current therapeutic options (2003) (5)
- Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis (2021) (5)
- Superiority of tirapazamine-containing chemoradiation in head and neck cancers showing evidence of hypoxia on 18F-misonidazole (FMISO) pet scanning (2004) (5)
- 915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (2020) (5)
- Comparison of neutropenia in a randomized, crossover trial of 3-, 6-, and 24-h infusions of paclitaxel. (2003) (5)
- KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC). (2018) (5)
- Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (2021) (5)
- Does biomodulation of 5-fluorouracil improve results? (1999) (5)
- Hypocalcemia associated with bone metastases in a patient with salivary-gland carcinoma (2006) (4)
- Sexual Health and Interpersonal Relationships Following Chemoradiotherapy For Human Papillomavirus Associated Oropharyngeal Cancer : a cross-sectional study. (2020) (4)
- Cancer Therapy : Clinical IL 6-STAT 3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer (2011) (4)
- Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II). (1996) (4)
- Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. (2022) (4)
- Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts. (2018) (4)
- Long‐term survival following chemoradiation for inoperable non‐small cell lung cancer (2008) (4)
- Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma (2022) (4)
- Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103) (2018) (4)
- Phase I, pharmacokinetic, and pharmacodynamic evaluation of BNC105P, a novel anticancer agent that is both a vascular disrupting agent (VDA) and an inhibitor of cancer cell proliferation. (2009) (4)
- 1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC) (2020) (4)
- Prechemotherapy hepatitis B virus (HBV) screening in medical oncology patients: A national survey. (2010) (4)
- Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies (2019) (4)
- Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial - A Trans-Tasman Radiation Oncology Group study. (2020) (4)
- Further clinical interpretation and implications of KEYNOTE-048 findings – Authors' reply (2020) (4)
- A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS). (2016) (4)
- A phase I pharmacokinetic study of PR-104, a hypoxia-targeting agent, in patients with solid tumors (2007) (3)
- A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer (2004) (3)
- A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapy (2022) (3)
- A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin (2022) (3)
- A phase II trial of preoperative radiotherapy with protracted infusion 5-fluorouracil for resectable adenocarcinoma of rectum. A multi-center trial for the Trans-Tasman Radiation Oncology Group (2000) (3)
- Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial (2010) (3)
- The contribution of cytotoxic chemotherapy to the management of cancer. (2005) (3)
- Correlation of HPV status and hypoxic imaging using [18F]-misonidazole (FMISO) PET in head and neck squamous cell carcinoma (HNSCC). (2011) (3)
- Carboplatin dosing based on estimated Glomerular Filtration Rate (GFR) using IDMS creatinine: A comparison of estimated GFR based on IDMS creatinine in the Cockroft-Gault (CG) formula (IDMS-GFR), with measured GFR using 51Cr-EDTA (51Cr-GFR). (2015) (3)
- Radiation oncology outpatient medication management needs and service gaps – A cross-sectional study of patients and clinicians (2019) (3)
- 585 First-in-man, Multicenter, Phase I Trial Evaluating the Safety of First-in-class Therapeutic, EGFR-targeted, Paclitaxel-Packaged Minicells (2012) (3)
- Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2018) (3)
- Comparison of bedside estimates of renal function and measured glomerular filtration rate (GFR) in 510 adult oncology patients (2007) (3)
- Pseudotumor presentation of CMV disease: Diagnostic dilemma and association with immunomodulating therapy (2020) (3)
- Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 (‘Iressa’) in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition (2001) (3)
- Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up (2020) (3)
- A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC) (2019) (3)
- Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma (2021) (3)
- Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma (2021) (3)
- Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort. (2021) (3)
- 491 The prognostic significance of 18F-misonidazole (FMISO) PET-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with and without tirapazamine (2004) (2)
- Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol (2021) (2)
- Prognostic significance of interleukin-8 (IL-8) and hepatocyte growth factor (HGF) in patients with head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on a phase III trial. (2010) (2)
- Comparison of self-reported smoking status and physician-recorded smoking status among patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). (2011) (2)
- Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors: Results from a phase I study (2001) (2)
- Locoregional Radiation Therapy for De Novo Metastatic Nasopharyngeal Cancer: One Size Fits All? (2021) (2)
- A Phase II Trial of Carboplatin and Etoposide for Relapsed or Metastatic Carcinoma of the Cervix (1998) (2)
- Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study (2019) (2)
- Differential Mechanisms of CDKN2A (p16) Inactivation in Oral Tongue Squamous Cell Carcinomas and Correlation With Patient Outcome (2014) (2)
- Impact of p16 status on the QOL effects of chemoradiation for locally advanced oropharynx cancer: Results of TROG 02.02. (2012) (2)
- INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2020) (2)
- Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial (2020) (2)
- Superiority of tirapazamine-containing chemoradiation in head and neck cancers showing evidence of hypoxia on 18F-misonidazole (FMISO) pet scanning. (2004) (2)
- Surgical management of recurrent cutaneous squamous cell carcinoma of the head and neck after definitive surgery and radiotherapy. (2020) (2)
- Chapter 47 – Management of Complications of Chemotherapy (2004) (2)
- President Recent Work Title Quantitative and qualitative analysis of [ F-18 ] FDG and [ F-18 ] FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome (2018) (2)
- Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer. (2010) (2)
- Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) (2018) (2)
- Impact of Prior Lines of Systemic Therapy (PST) on the Efficacy Of Cemiplimab, a Human Monoclonal Anti–PD-1, in Patients (PTS) with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) (2019) (2)
- Delayed relapse following preoperative chemoradiation and surgery for rectal cancer (2003) (2)
- A first-in-human, phase I pharmacodynamic (PD) and pharmacokinetic (PK) study of BNC105P, a novel vascular disrupting agent (VDA) and inhibitor of cancer cell proliferation. (2010) (2)
- Contralateral neck failure in oral tongue cancer: Outcomes from two centers using predefined treatment criteria (2021) (2)
- Prognostic stratification of HPV associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomised trials. (2022) (2)
- Prognostic significance of plasma osteopontin in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on TROG 02.02 phase III trial. (2011) (1)
- Recurrent intestinal type sinonasal adenocarcinoma treated with FOLFOX6 chemotherapy: Case report and review of literature (2012) (1)
- Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma (2018) (1)
- Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas (2016) (1)
- 1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS] (2021) (1)
- Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state. (2020) (1)
- A phase I study of the vascular-disrupting agent BNC105P in combination with gemcitabine-carboplatin in platinum-sensitive ovarian cancer patients in first or second relapse. (2014) (1)
- Promising New Approaches in the Treatment of Advanced Head and Neck Cancer (2003) (1)
- The Changing Demography and Treatment of Nasopharyngeal Carcinoma in Melbourne from 1985–2000 (2003) (1)
- Results of treatment intensification for progressive locoregional disease in head-and-neck cancer patients undergoing postoperative radiotherapy. (2005) (1)
- P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 (2021) (1)
- Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274) (2019) (1)
- Dose escalation study of concurrent carboplatin and fluorouracil with radical radiotherapy [RT] in non-small cell lung cancer (2000) (1)
- Outcomes of curative (chemo)radiotherapy for patients with non‐p16 positive head and neck squamous cell carcinoma who are borderline for curative treatment (2020) (1)
- 789O Neoadjuvant cemiplimab in patients (pts) with stage II–IV (M0) cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study (2022) (1)
- F-18 Fluorodeoxyglucose (FDG) PET and Indium-111 SPECT scans to track the biodistribution of macrophage-activated killer (MAK) cells linked with MDX-H210 in patients with epithelial ovarian cancer. (2004) (1)
- Functional and molecular biomarker analysis demonstrates pharmacological activity for the novel vascular disrupting agent BNC105 in a first in human clinical study (2011) (1)
- 547 CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (2021) (1)
- Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232. (2021) (1)
- A Critical Review of 25 Years of Clinical Trials (1)
- Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials. (2021) (1)
- 1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results (2021) (1)
- Molecular insights influencing the management of head and neck cancers (2015) (1)
- PET response is the most powerful predictor of survival after radical radiotherapy/chemoradiotherapy for unresectable non-small cell lung cancer (2001) (1)
- Transoral Surgery and Deintensified Adjuvant Therapy: Another Step in Determining Its Role in the Management of Human Papillomavirus Oropharyngeal Cancer. (2021) (1)
- Radiation with cisplatin or carboplatin for locally advanced cervix cancer: The experience of a tertiary cancer center (2012) (1)
- Treatment of hypercalcemia of malignancy with intermittent single infusions of 3-amino-1-hydroxypropylidene-1, 1-biphosphonate (APD) (1988) (1)
- Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts (2018) (1)
- A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug, in patients with solid tumors (2008) (1)
- Relationship between epidermal growth factor receptor (EGFR) gene copy number, p16 status, and outcome in locally advanced squamous cell carcinoma of the head and neck (LASCCHN). (2010) (1)
- Leptomeningeal metastases from anaplastic thyroid carcinoma. (2000) (1)
- 351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 (2020) (1)
- Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (2017) (1)
- Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome (2014) (1)
- Discovery and clinical development of BNC105, a tubulin targeting small molecule that selectively disrupts the vasculature in solid tumours (2011) (1)
- A phase I study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer (2007) (1)
- 263 POSTER Metabolism and pharmacokinetics of PR-104, a hypoxia-activated nitrogen mustard prodrug in phase I clinical trial (2006) (0)
- Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors (2021) (0)
- Update of Immune Therapies in Recurrent/Metastatic Head and Neck Cancer (2021) (0)
- Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3 (2023) (0)
- BRAF Inhibition in BRAF V 600 E-Positive Anaplastic Thyroid Carcinoma (2016) (0)
- 164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy (2021) (0)
- Extradural malignancy simulating brachial neuritis. (1986) (0)
- QOL for Advanced Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Randomized Trial of Tirapazamine, Cisplatin, and Radiation vs. Cisplatin and Radiation (TROG 02.02) (2009) (0)
- In‐transit cutaneous squamous cell carcinoma (2022) (0)
- Sexual Satisfaction and Relationship Status in Long-term Survivors of Human Papillomavirus-Associated Oropharyngeal Carcinoma (2019) (0)
- 1PDA high throughput compound screen identifies potential combinations to overcome resistance to Cdk2 inhibitors in Cyclin E1 amplified high grade serous ovarian cancer (2015) (0)
- Reassessing Locus-Specific DNA Methylation in Head-and-Neck Squamous Cell Carcinoma (HNSCC) With Quantitative Methodology and Correlation With Patient Outcome (2014) (0)
- An evaluation of health literacy in a consecutive sample of patients with cancer of the head and neck (H+N) region (2010) (0)
- Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study. (2019) (0)
- GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. (2018) (0)
- The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection. (2022) (0)
- P-88 First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study (2021) (0)
- The "quad shot" - palliative radiotherapy in locally advanced head and neck squamous cell carcinoma (2005) (0)
- A clinical trial with protracted infusion 5‐fluorouracil and mitomycin C for localized squamous cell carcinoma of the anus (2018) (0)
- 885TiP The I-PACE study: Imgatuzumab in PAtients with advanCEd cutaneous squamous cell carcinoma (aCSCC) (2022) (0)
- Pharmacodynamic S tudies o f t he E pidermal G rowth F actor Receptor I nhibitor Z D1839 i n S kin F rom C ancer P atients: Histopathologic a nd M olecular C onsequences o f Receptor I nhibition (2002) (0)
- The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma (2022) (0)
- Prognostic and Predictive Signi fi cance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer (2012) (0)
- An evaluation of health literacy (HL) in a consecutive sample of patients (pts) with cancer (ca) of the head and neck (H+N) region. (2010) (0)
- High-Risk M erkel C ell C arcinoma o f t he S kin T reated W ith Synchronous C arboplatin/Etop oside a nd R adiation: A T rans- Tasman R adiation O ncology G roup S tudy—TROG 9 6:07 (2003) (0)
- Quality of life and functioning in HPV associated oropharyngeal cancer survivors (2020) (0)
- 1087P Time to clinically meaningful changes in pain in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in a phase II clinical trial (2020) (0)
- Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer (2022) (0)
- Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial (2021) (0)
- OC-0364: Impact of imaging and pathological biomarkers on survival after chemoradiation of locally advanced cervical cancer (2014) (0)
- Drugging Tumour Hypoxia: Resolving the Complexity Using Functional Genetic Screens (2015) (0)
- 11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study (2020) (0)
- A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours (2021) (0)
- Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. (2023) (0)
- Feasibility of implementing a pharmacist-led DPYD gene testing service for patients commencing 5-fluorouracil (5FU) or capecitabine. (2021) (0)
- Short communication Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer (2000) (0)
- A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer. (1992) (0)
- EP-1087: Post treatment PET-CT to stratify follow-up for head and neck cancers - a matched cohort analysis of safety and cost (2014) (0)
- PD-0822 Impact of radiotherapy laterality on patient-reported outcomes in T1-2 HPV tonsillar carcinoma (2022) (0)
- P-603 Symptom response following high dose (HD) palliative radiotherapy (RT) plus concurrent weekly vinorelbine (V) and cis-platinum (C) in patients with locally advanced and metastatic non-small cell lung cancer (NSCLC): Results of a phase-I study (2003) (0)
- GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer (2020) (0)
- 373TiPKEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (2017) (0)
- Cancer Therapy : Preclinical Resistance toCDK 2 Inhibitors IsAssociatedwithSelection of Polyploid Cells in CCNE 1-Ampli fi ed Ovarian Cancer (2013) (0)
- PA-01 : A Phase 2 , Multicenter , Double-Blind , Randomized , Vehicle Controlled Clinical Study to Assess the Synergistic Effect of a Halobetasol / Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis (2019) (0)
- C-POST Protocol Update: A Phase 3, Randomized, Double-Blind Study of Adjuvant Cemiplimab vs. Placebo Post Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma (2022) (0)
- Survival With Cemiplimab in Recurrent Cervical Cancer (2022) (0)
- Induction Chemotherapy in Head and Neck Cancer (2005) (0)
- Weekly cisplatin and radiotherapy for low-risk human papillomavirus positive oropharyngeal squamous cell carcinoma (HPVOPC). (2014) (0)
- PO-0791: Sexual health in HPV-related oropharyngeal cancer survivors after (chemo)radiotherapy (2020) (0)
- Prognostic Signi fi cance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02 . 02 Phase III Trial (2011) (0)
- Phase I study of docetaxel epirubicin and cyclophosphamide (TEC) in patients with advanced cancer (AC) (1999) (0)
- Multi-Institutio nal R andomized P hase I I T rial o f G efitinib f or Previously T reated P atients W ith A dvanced N on-Small-Cell Lung C ancer (2003) (0)
- 973TiP LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (2020) (0)
- The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma (2018) (0)
- Gemcitabine for patients with relapsed nasopharyngeal carcinoma (2002) (0)
- Analogues and Cytosine Arabinoside in Myeloid Leukemia Altered Multidrug Resistance Phenotype Caused by Anthracycline (2013) (0)
- 1105TiPPembrolizumab plus chemoradiation (CRT) for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Phase 3 KEYNOTE-412 trial (2017) (0)
- Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma (2018) (0)
- Biomarkers for Immune Modulatory Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) (2021) (0)
- Prognostic biomarkers in locally advanced cervical cancer (Cx Ca) treated with chemoradiation (CRT) (2016) (0)
- Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy (2022) (0)
- Use of 18F-HX4 PET/CT to estimate tumor hypoxia enrolled subjects from ongoing Phase 2 trials using tarloxotinib bromide in advanced NSCLC and SCCHN. (2016) (0)
- Title Prognostic significance of plasma osteopontin in patients with loco-regionally advanced head and neck squamous cell carcinoma treated on TROG 02 . 02 Phase III trial (2011) (0)
- CliniMACS CD34-selected cells to support high-dose therapy (2001) (0)
- A phase I/II study of the vascular disrupting agent BNC105P in combination with gemcitabine-carboplatin in partially platinum-sensitive ovarian cancer patients in first or second relapse: An international collaborative group trial of ANZGOG and HOG. (2013) (0)
- The utility of PET for the detection of disease in residual neck nodes following (chemo)radiotherapy in head and neck cancer (2004) (0)
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2022) (0)
- List of Contributors (2019) (0)
- Cancer Therapy : Clinical Clinical , Pharmacodynamic , and Pharmacokinetic Evaluation of BNC 105 P : A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation (2011) (0)
- 75 Can hypoxia imaging be used to identify patients for tirapazamine-based therapy? (2006) (0)
- 814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3 (2022) (0)
- Phase I trial of gefitinib in combination with concurrent carboplatin, paclitaxel and radiation therapy (RT) in patients with stage III non-small-cell lung cancer (NSCLC) (2004) (0)
- A Phase 3 randomized Double-blind Study of adjuvant Cemiplimab versus Placebo after Surgery and Radiotherapy for Patients with cutaneous squamous Cell Carcinoma Patients with high Risks (2020) (0)
- Head and Neck Symptom Severity (HNSS) and Health-Related Quality of Life (HRQL) Trajectories during and after Chemoradiotherapy (CRT) for HPV-Associated Oropharyngeal Cancer (HPVOPC): A TROG 12.01 Secondary Analysis (2022) (0)
- Abstract 4693: Characterization of the differential mechanisms ofCDKN2Ainactivation in oral tongue squamous cell carcinomas and correlation with patient outcome. (2013) (0)
- Current Controversies in Cancer Does Biomodulation of 5-Fluorouracil Improve Results? (1999) (0)
- 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048 (2022) (0)
- 818P Phase II confirmatory study of cemiplimab (350mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6 (2022) (0)
- 1259 Real world experience of immunotherapy in an elderly trial-ineligible cohort of patients with advanced cutaneous squamous cell carcinoma (2022) (0)
- M OLECULAR INSIGHTS INFLUENCING THE MANAGEMENT OF HEAD AND NECK CANCERS (2015) (0)
- Patient-report symptom severity, health-related quality of life and emotional distress trajectories during and after radiotherapy for HPV-associated oropharyngeal cancer: a XXXX.XXXX secondary analysis. (2023) (0)
- Phase I study of repetitive high-dose topotecan (T) carboplatin (C) and paclitaxel (P) in previously untreated ovarian cancer (1999) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Danny Rischin?
Danny Rischin is affiliated with the following schools: